Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | KCNA3 | P22001 | 2/20 | 0.33 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14943802 | 0.83 | KCNA3 (0.30) | KCNA3 | |
| SCHEMBL1468175 | 0.81 | — | — | |
| SCHEMBL15967442 | 0.81 | NPSR1 (0.35) | MEN1KMT2AKCNA3 | |
| SCHEMBL15967438 | 0.81 | FFAR3 (0.31) | FFAR3 | |
| SCHEMBL15967454 | 0.78 | KCNA3 (0.35) | MEN1CYP2C9KMT2AKCNA3 | |
| SCHEMBL2300431 | 0.77 | FFAR3 (0.38) | MEN1KMT2AFFAR3 | |
| SCHEMBL5634851 | 0.77 | — | — | |
| Hydrochloric Acid SCHEMBL11387822 | 0.75 | FFAR3 (0.36) | FFAR3 | |
| SCHEMBL19233 | 0.75 | CYP2C19 (0.38) | MEN1KMT2AFFAR3 | |
| SCHEMBL2572504 | 0.73 | ALDH1A1 (0.35) | CYP2C9FFAR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230157999-A1 | PYRANO[4,3-B]INDOLE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) | VERTEX PHARMACEUTICALS (SAN DIEGO) LLC | 2023-05-25 | — | — | US | disclosed |
| WO-2021203014-A1 | PYRANO[4,3-B]L NDOLE DERIVATIVES AS ALPHA-1 -ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1 -ANTITRYPSIN DEFICIENCY (AATD) | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-10-07 | — | — | WO | disclosed |
| EP-3371171-A1 | INHIBITORS OF RET | Blueprint Medicines Corporation (US) | 2018-09-12 | — | — | EP | disclosed |
| WO-2017079140-A1 | INHIBITORS OF RET | BLUEPRINT MEDICINES CORPORATION (US) | 2017-05-11 | — | — | WO | disclosed |
| US-9249180-B2 | C-3 alkyl and alkenyl modified betulinic acid derivatives | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-02-02 | — | — | US | disclosed |
| US-9249180-B2 | C-3 alkyl and alkenyl modified betulinic acid derivatives | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-02-02 | — | — | US | disclosed |
| US-9249180-B2 | C-3 alkyl and alkenyl modified betulinic acid derivatives | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-02-02 | — | — | US | disclosed |
| EP-2958930-A1 | C-3 ALKYL AND ALKENYL MODIFIED BETULINIC ACID DERIVATIVES USEFUL IN THE TREATMENT OF HIV | Bristol-Myers Squibb Company (US) | 2015-12-30 | — | — | EP | disclosed |
| US-20140243298-A1 | C-3 ALKYL AND ALKENYL MODIFIED BETULINIC ACID DERIVATIVES | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2014-08-28 | — | — | US | disclosed |
| US-20140243298-A1 | C-3 ALKYL AND ALKENYL MODIFIED BETULINIC ACID DERIVATIVES | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2014-08-28 | — | — | US | disclosed |
| US-20140243298-A1 | C-3 ALKYL AND ALKENYL MODIFIED BETULINIC ACID DERIVATIVES | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2014-08-28 | — | — | US | disclosed |
| WO-2014130810-A1 | C-3 ALKYL AND ALKENYL MODIFIED BETULINIC ACID DERIVATIVES USEFUL IN THE TREATMENT OF HIV | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-08-28 | — | — | WO | disclosed |
| WO-2014130810-A1 | C-3 ALKYL AND ALKENYL MODIFIED BETULINIC ACID DERIVATIVES USEFUL IN THE TREATMENT OF HIV | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140243298-A1 | C-3 ALKYL AND ALKENYL MODIFIED BETULINIC ACID DERIVATIVES | BET1, TMPO, PGGT1B | MEN1 3602/4885CYP2C9 439/4885KMT2A 3728/4885 |
| US-20230157999-A1 | PYRANO[4,3-B]INDOLE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) | SERPINA2, SERPINB1, SERPINE1 | MEN1 1802/4885CYP2C9 3054/4885KMT2A 4356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.